Therapy News and Research

RSS

Study uncovers new mechanism of action in a first-line drug for diabetes

For decades, metformin has been the first-line drug in the treatment of type 2 diabetes, lowering blood glucose levels by inhibiting glucose production in the liver. Metformin also improves glucose uptake and use by muscle tissue.

23 Oct 2018

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Patients with an aggressive form of advanced breast cancer can benefit from immunotherapy when used in combination with chemotherapy as first-line treatment, according to the results of a large international Phase III clinical trial published today in the New England Journal of Medicine and led by a researcher at the UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine.

23 Oct 2018

Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy

Treatment with the cyclin dependent kinase 4/6 inhibitor palbociclib achieves a clinically meaningful improvement in overall survival in patients with hormone receptor positive human epidermal growth factor receptor-2 negative advanced breast cancer that has relapsed or progressed on hormonal therapy, according to the final analysis of overall survival results from the PALOMA-3 study reported at ESMO 2018.

23 Oct 2018

Drugs approved for breast cancer treatment are effective and well tolerated in men

There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the largest real-life study yet to investigate treatment and outcomes in men with breast cancer and two further studies to be reported at ESMO 2018.

23 Oct 2018

Novartis: Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients

Novartis announced today that the full data from the LIBERTY study of Aimovig (erenumab) in episodic migraine patients who had tried and failed two to four prior preventive treatments have been published in the Lancet.

23 Oct 2018

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie, a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis.

23 Oct 2018

Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC

Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, today announced that the first patient has been dosed in a Phase 2a trial evaluating the efficacy and safety of AVID100 in patients with squamous non-small cell lung cancer whose tumors overexpress epidermal growth factor receptor.

23 Oct 2018

Construction is underway for second proton therapy system at Siteman Cancer Center

Mevion Medical System announces that construction is underway for a second proton therapy system at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. T

23 Oct 2018

New discovery may lead to better treatment options for pancreatic cancer patients

Pancreatic cancer is one of the most difficult cancers to treat and is a leading cause of cancer-related deaths. Now, Sidney Kimmel Cancer Center - Jefferson Health and Lankenau Institute for Medical Research scientists find that a gene involved in the immune system called IDO2 plays a significant role in pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer.

23 Oct 2018

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Immunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer, according to surprising new data from a major phase III clinical trial.

23 Oct 2018

Salk researchers advance sonogenetics technology for treating neurological conditions

The emerging technology of sonogenetics--a technique where cells are controlled by sound--offers the potential to one day replace pharmaceutical drugs or invasive surgical treatments for neurological conditions like epilepsy, Parkinson's disease or posttraumatic stress disorder.

23 Oct 2018

NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors

A new program project grant from the National Cancer Institute will fund research by the Translational Center of Excellence for Lung Cancer Immunology at the Abramson Cancer Center of the University of Pennsylvania to improve the effectiveness of chimeric antigen receptor T cell therapy at fighting solid tumors.

23 Oct 2018

Radiotherapy combined with androgen-deprivation therapy improves overall survival up to 10 years

The long-term follow up of the NRG Oncology trial RTOG 9408, studying the addition of short-term androgen-deprivation therapy (ADT) to radiotherapy (RT) for men with early, localized prostate adenocarcinoma, indicated that RT combined with ADT is superior to RT alone for overall survival up to 10.4 years following treatment.

23 Oct 2018

Cancer treatment may undergo a paradigm shift to immunotherapy soon

Immunotherapy when used for cancer treatment could extend life longer finds studies. Experts have explained that until now immunotherapy was reserved as a last resort for most patients and treatment usually comprised of chemotherapy and radiation therapy failing which these were tried. In a pair of clinical trials, researchers have found that using immunotherapy as first line treatment can extend lives of these cancer patients.

23 Oct 2018

Patient-reported data confirms efficacy of brachytherapy alone in intermediate risk prostate cancer

Oncology trial RTOG 0232 comparing a combined treatment of external beam therapy and brachytherapy to transperineal interstitial permanent brachytherapy alone indicate a significantly different clinician and patient-reported late toxicity profile between arms despite similarities in progression-free survival results.

22 Oct 2018

Study: Targeting specific genomic mutation in breast cancer improves survival

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.

22 Oct 2018

Therapy News and Research

Study uncovers new mechanism of action in a first-line drug for diabetes

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy

Drugs approved for breast cancer treatment are effective and well tolerated in men

Novartis: Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC

Construction is underway for second proton therapy system at Siteman Cancer Center

New discovery may lead to better treatment options for pancreatic cancer patients

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Salk researchers advance sonogenetics technology for treating neurological conditions

NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors

Radiotherapy combined with androgen-deprivation therapy improves overall survival up to 10 years

Cancer treatment may undergo a paradigm shift to immunotherapy soon

Patient-reported data confirms efficacy of brachytherapy alone in intermediate risk prostate cancer

Study: Targeting specific genomic mutation in breast cancer improves survival

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Targeted drug and hormone therapy combination extends breast cancer survival

People with periodontal disease less likely to reach healthy blood pressure ranges

IDT to demonstrate CRISPR expertise at European-focused events

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News